|
US6924123B2
(en)
*
|
1996-10-29 |
2005-08-02 |
Oxford Biomedica (Uk) Limited |
Lentiviral LTR-deleted vector
|
|
US6319905B1
(en)
|
1998-12-29 |
2001-11-20 |
Cell Genesys, Inc. |
Method of controlling L-Dopa production and of treating dopamine deficiency
|
|
GB0024550D0
(enExample)
|
2000-10-06 |
2000-11-22 |
Oxford Biomedica Ltd |
|
|
US6933377B2
(en)
*
|
2002-07-29 |
2005-08-23 |
Qun Chen |
Compositions comprising multiple immunodeficiency virus subunits for inducing an immune response
|
|
ES2831031T3
(es)
*
|
2003-05-16 |
2021-06-07 |
Acorda Therapeutics Inc |
Proteínas de fusión para el tratamiento del CNS
|
|
US20100189727A1
(en)
*
|
2008-12-08 |
2010-07-29 |
Tegopharm Corporation |
Masking Ligands For Reversible Inhibition Of Multivalent Compounds
|
|
WO2012135389A2
(en)
*
|
2011-03-28 |
2012-10-04 |
The Regents Of The University Of California |
Host cells and methods for oxidizing aromatic amino acids
|
|
JP6698114B2
(ja)
*
|
2011-10-28 |
2020-05-27 |
オックスフォード バイオメディカ （ユーケー） リミテッド |
構築物
|
|
GB201118636D0
(en)
*
|
2011-10-28 |
2011-12-07 |
Oxford Biomedica Ltd |
Nucleotide sequence
|
|
US10400252B2
(en)
*
|
2011-10-28 |
2019-09-03 |
Oxford Biomedica (Uk) Ltd. |
Catecholamine enzyme fusions
|
|
RS64664B1
(sr)
|
2013-02-15 |
2023-11-30 |
Bioverativ Therapeutics Inc |
Gen optimizovanog faktora viii
|
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
|
PH12018501628B1
(en)
|
2016-02-01 |
2023-11-10 |
Bioverativ Therapeutics Inc |
Optimized factor viii genes
|
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
US20200048332A1
(en)
|
2016-10-12 |
2020-02-13 |
Bioverativ Usa Inc. |
Anti-c1s antibodies and methods of use thereof
|
|
US11332521B2
(en)
|
2016-11-07 |
2022-05-17 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
KR20220031738A
(ko)
|
2017-06-27 |
2022-03-11 |
주식회사 뉴라클사이언스 |
암 치료를 위한 항-fam19a5 항체의 용도
|
|
BR112019027729A2
(pt)
|
2017-06-27 |
2020-08-18 |
Neuracle Science Co., Ltd |
anticorpos anti-fam19a5 e seus usos
|
|
WO2019003159A1
(en)
|
2017-06-27 |
2019-01-03 |
Neuracle Science Co., Ltd. |
USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF FIBROSIS
|
|
KR102511122B1
(ko)
|
2017-06-27 |
2023-03-22 |
주식회사 뉴라클사이언스 |
녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도
|
|
TWI823868B
(zh)
|
2017-10-11 |
2023-12-01 |
美商生物維瑞提夫美國公司 |
誘導補體活性之方法
|
|
JP2021512126A
(ja)
|
2018-02-01 |
2021-05-13 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ｖｉｉｉ因子を発現するレンチウイルスベクターの使用
|
|
KR20240001331A
(ko)
|
2018-04-24 |
2024-01-03 |
주식회사 뉴라클사이언스 |
신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
|
|
CN112119091B
(zh)
|
2018-05-10 |
2025-01-03 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体及其使用方法
|
|
MX2020013923A
(es)
|
2018-06-29 |
2021-03-29 |
Apitbio Inc |
Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
|
|
CN119185536A
(zh)
|
2018-10-16 |
2024-12-27 |
纽洛可科学有限公司 |
抗fam19a5抗体的用途
|
|
JP2022507606A
(ja)
|
2018-11-16 |
2022-01-18 |
ネオイミューンテック， インコーポレイテッド |
Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
|
|
CN113396223A
(zh)
|
2018-12-06 |
2021-09-14 |
比奥维拉迪维治疗股份有限公司 |
表达因子ix的慢病毒载体的用途
|
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
|
CN113227139B
(zh)
|
2018-12-27 |
2024-10-29 |
纽洛可科学有限公司 |
抗fam19a5抗体治疗动脉粥样硬化的用途
|
|
KR20240049652A
(ko)
|
2019-01-02 |
2024-04-16 |
주식회사 뉴라클사이언스 |
항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체 및 이의 사용 방법
|
|
CN115279896A
(zh)
|
2019-09-30 |
2022-11-01 |
比奥维拉迪维治疗股份有限公司 |
慢病毒载体配制品
|
|
US20230057939A1
(en)
|
2020-01-13 |
2023-02-23 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
|
|
WO2021151001A1
(en)
|
2020-01-22 |
2021-07-29 |
Outpace Bio, Inc. |
Chimeric polypeptides
|
|
EP4093752A2
(en)
|
2020-01-22 |
2022-11-30 |
Outpace Bio, Inc. |
Chimeric polypeptides
|
|
EP4100045A1
(en)
|
2020-02-05 |
2022-12-14 |
Washington University |
Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
|
|
IL299333A
(en)
|
2020-06-24 |
2023-02-01 |
Bioverativ Therapeutics Inc |
Methods for the purification of viral vectors
|
|
US20230398216A1
(en)
|
2020-10-22 |
2023-12-14 |
Lyell Immunopharma, Inc. |
Chimeric activation receptors
|
|
US20230398184A1
(en)
|
2020-10-26 |
2023-12-14 |
Neoimmunetech, Inc. |
Methods of inducing stem cell mobilization
|
|
US20240101629A1
(en)
|
2020-11-02 |
2024-03-28 |
Neoimmunetech, Inc. |
Use of interleukin-7 for the treatment of coronavirus
|
|
IL302482A
(en)
|
2020-11-05 |
2023-06-01 |
Neoimmunetech Inc |
Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
|
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
|
EP4347826A1
(en)
|
2021-06-02 |
2024-04-10 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
|
WO2023056331A1
(en)
|
2021-09-30 |
2023-04-06 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
|
EP4430047A1
(en)
|
2021-11-08 |
2024-09-18 |
Progentos Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
|
WO2023130081A1
(en)
|
2021-12-30 |
2023-07-06 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
|
JP2025528742A
(ja)
|
2022-07-28 |
2025-09-02 |
ステムセル テクノロジーズ カナダ インコーポレイテッド |
連結された抗原をコードするポリヌクレオチド及びその使用
|
|
KR20250089492A
(ko)
|
2022-11-07 |
2025-06-18 |
네오이뮨텍, 인코퍼레이티드 |
비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법
|
|
WO2025010272A1
(en)
|
2023-07-03 |
2025-01-09 |
Neoimmunetech, Inc. |
Heterodimeric fc molecules and uses thereof
|